



INSIDE

Career: How to Prepare for Your Physician Job Interview. Pg. 1

Career: Physician Employment Contracts: Strategies for Avoiding Pitfalls. Pg. 4

Clinical: Postmenopausal Osteoporosis, as published in the *New England Journal of Medicine*. Pg. 10

The latest physician jobs brought to you by the NEJM CareerCenter

Residents and Fellows Edition

Featured Employer Profile

The logo for Optum, featuring the word "Optum" in a bold, orange, sans-serif font.



February 15, 2024

Dear Physician:

As you approach the completion of your training, I'm sure that finding the right opportunity for you is a top priority. The *New England Journal of Medicine* (NEJM) is the leading source of information about job openings, especially practice opportunities, in the country. To assist you in this important search, a complimentary reprint of the physician job openings section of the February 15, 2024, issue is enclosed. You may also find these job openings on the NEJM Career Center website at nejmcareercenter.org.

Designed specifically based on advice from your colleagues, the NEJM CareerCenter website offers physician users many confidentiality safeguards that keep your personal information and job searches private. At NEJM CareerCenter, you will find:

- Quality, current locum tenens and permanent openings — not jobs that were filled months ago
- Email alerts that automatically notify you about new opportunities
- Sophisticated search capabilities to help you pinpoint jobs that match your search criteria
- A comprehensive resources center with career-focused articles and job-seeking tips
- An iPhone app that allows you to search and apply for jobs with a touch of a button

Additionally, if you are not currently an NEJM subscriber, I invite you to visit NEJM.org to become one. As you move forward in your career, you will find that every weekly issue of NEJM contains information you will use daily as you see patients, presented in a clinically useful format. One example is the popular Clinical Practice articles that offer evidence-based reviews of topics relevant to practicing physicians. Read “Postmenopausal Osteoporosis” from the November 23, 2023, issue which is included as a reprint in this special booklet.

Other online features on NEJM.org include Videos in Clinical Medicine, which allows you to watch common clinical procedures, and Interactive Medical Cases, which presents an evolving patient history and a series of questions and exercises designed to test your diagnostic and therapeutic skills.

On behalf of the entire *New England Journal of Medicine* staff, please accept my wishes for a rewarding career.

Sincerely,

Eric J. Rubin, MD, PhD



How to Prepare for Your Physician Job Interview

By Nisha Mehta, MD, a physician leader whose work focuses on physician empowerment, community building, and career longevity in medicine

Finally! You've done countless interviews at this point, but for many of you, this is the first one where you are interviewing for a “real job.” Some of the same rules apply, but others are very different.

To start, the dynamic in this interview is much different than others. You are likely interviewing with people who will be your colleagues, and your impression of them counts just as much as their impression of you. Depending on the job market in your field, there's a distinct possibility that they may even need you more than you need them.

Additionally, in an ideal scenario, you are picking a job that will last longer than a set time period of training. You are designing what potentially decades of life could look like for you and your family. Since this isn't just a stepping stone to the next thing, your approach will need to be more all-inclusive. Also, unlike residencies and fellowships, where a similar core set of responsibilities and expectations are already outlined, there is a lot of variability between jobs, even within the same city and specialty. It's important you are able to leave the interview with a 360-degree view of the position and the life you will build around it.

Career Resources articles posted on NEJM CareerCenter are produced by freelance health care writers as an advertising service of NEJM Group, a division of the Massachusetts Medical Society, and should not be construed as coming from the *New England Journal of Medicine*, nor do they represent the views of the *New England Journal of Medicine* or the Massachusetts Medical Society.


Keeping all of that in mind, here are some of my core tips for preparing for an interview:

- 1. Do your research about a job ahead of time.** Not doing this is one of the biggest mistakes I see applicants making. Showing up to a job and asking basic questions whose answers can easily be found online will cause interviewers to question why you're at the interview and how serious you are about the job. You want to come in knowing how the group is structured from a management perspective, what its patient population looks like, who the referral base may be, and what areas within your field the group specializes in, as well as some areas or topics where you may be able to add value. Look at the group's website and the members and see if there are any connections that you might have where you might be able to find common ground. Call the people you know who may be familiar with the group and ask them for insights. Find out if people have left the group recently, as it may raise some red flags. This will all lead to more sophisticated questions that you can ask and more valuable information to consider when you are making your decision. It will also tell group members you are serious about the opportunity, which will help your chances as they decide whether to extend a job offer. Time and resources are precious in this process, and many won't want to waste their time if they feel they are one of 100 possibilities.
- 2. Try and allot time to get to know the city you are interviewing in.** For those of you who are trying to return to a known place, this may be less of an issue, but nonetheless, training somewhere or growing up somewhere is different from living there as an adult and potentially raising a family in that location. Make sure the place offers outlets to foster your interests outside of work, as it will play into your happiness and burnout. Tour neighborhoods you may want to live in, and if you have educational preferences for your children, take some time to explore your options. If applicable, bring your significant other with you so that you're on the same page about pros and cons of living there.
- 3. When interviewing with potential future colleagues, don't be afraid to be yourself.** It's important that the fit feels natural and that there is a mutual desire to work together. As the saying goes, you can't choose your family, but you can choose your friends. Similarly, you can choose colleagues that you are confident will contribute to your happiness at the job, whether it be via friendships, accommodating emergencies when they arise, splitting work in a way that feels equitable, or being respected.

You should see yourself fitting into the culture of the group's members and in line with the standards, ethics, and practice patterns that they embrace.

- 4. In a similar vein, take note of how colleagues are interacting with each other.** As the landscape of health care delivery gets more challenging and complicated, it's important that you feel that the group is cohesive and supports each other. If there are obvious tensions within the group, it may be a sign that there is more beneath the surface that's resulting in conflict, whether it's RVU (relative value unit) structures, partnership issues, different beliefs about the direction the company is taking, etc.
- 5. Talk about money and opportunities for growth.** After all, this is a job. Put some effort into figuring out how revenue is generated, when you get to share in those profits, and what the plans of the group are in terms of expansion. If the compensation structure is complicated, ask for details. You don't have to take up your entire interview time talking about it, but get a basic sense and then ask the interviewer to send you a summary with details later. Understand the benefits. If the group's members do something a lot different from other groups you've interviewed with or your colleagues are interviewing with, ask them why they chose to structure things in that way.
- 6. If possible, spend some time shadowing someone whose job is similar to the one you're interviewing for.** Make sure you can see yourself happy in his or her shoes, and if there are obvious pain points or dealbreakers, take note of them. You may not be able to do this on the day of the interview, but if you have doubts about whether you'd enjoy the particular setting ahead of time, see if an interviewer can incorporate this on a later date. Again, it's in everybody's best interest to ensure a job is a good fit for you.

I could go on, but your goal on your interview day is to confirm the job is one you can see yourself enjoying for years to come. You're really picking more than a job — you're picking a lifestyle and a vision for your future, and you want to make sure you are keeping a keen eye out for pros, cons, and red flags.

 Did you find this article helpful? Sign up for our Career Resources Update e-newsletter to get more physician career articles delivered right to your inbox! www.nejmcareercenter.org/register.



Physician Employment Contracts: Strategies for Avoiding Pitfalls

By Bonnie Darves, a Seattle-based freelance health care writer

As physicians increasingly opt for practice opportunities in employed-model arrangements and hiring entities move toward standardizing employment contracts to simplify matters and ensure equitable treatment of existing and incoming physicians, it might appear that there's scant room for negotiating contract terms.

That's not a prudent attitude to take about such an important document, contract lawyers maintain. That employment agreement not only dictates the next year or two of a physician's career but also could potentially negatively affect his or her personal and professional life for years into the future. Benjamin J. Mayer, JD, MBA, a Denver lawyer whose firm specializes in physician contracts, advises physicians to take the position that any terms that aren't favorable can — and should — be made more reasonable. "The physician might not be able to get a higher starting salary or a larger signing bonus but definitely should negotiate anything that's explicitly unfair or clearly intentionally ambiguous," Mr. Mayer said.

Key examples he cites are contracts with onerous non-compete provisions that would prevent a departing physician from working within, say, a 60-mile radius of any of the employer's locations, or contracts that contain little detail about weekly work hours and schedules, or call requirements.

Essentially, anything that is vague or an overreach should be modified and specified. "The physician needs to require reasonable boundaries on all of the contract's terms," Mr. Mayer said. For example, any non-compete radius should be drawn from a single primary location, not from all of a sprawling mega-health system's hospitals and clinics. Similarly, regarding schedules, the contract should at least specify a cap on total weekly hours or days worked and should dictate an equitable call schedule.

"Duties, hours, and responsibilities should be spelled out, and if the call coverage isn't specified, the contract should at least state that those duties will be 'equally divided among all physicians' in the group," Mr. Mayer said. He acknowledged that some young physicians might be willing to shoulder commensurately more call duty than their peers if they're trying to pay off medical school loans, for example, but such special arrangements are best addressed outside of the contract.

Michael Schaff, cochair of health law for Wilentz, Goldman & Spitzer, P.A. in Woodbridge, New Jersey, suggests that young physicians in surgical and other call-intensive specialties should determine whether practice culture or bylaws issues might translate into an inordinate call burden that they're not willing to assume. For example, Mr. Schaff noted, some practices enable physicians who reach a certain age — 55 or 60 is common — to opt out of call altogether. If several senior doctors stop taking call, younger physicians' "equally divided duties" might be unmanageable. To be safe, the contract should specify a "not to exceed" number of call days per week or month, Mr. Schaff and other sources advised.

Emerging "super groups" affect contracts

On a global scale, practice acquisition and management trends — specifically, the growing influence of private equity on physician practice and facility management and the creation of huge organizations that operate scores of groups — are affecting physician employment. Rebecca Gwilt, a Richmond, Virginia, lawyer and partner in Nixon Law Group, said she is witnessing a "trickle-down effect" on contracts as private equity-operated super groups emerge.

"We're seeing a more sophisticated framework for physician contracts," Ms. Gwilt said, as well as a tendency toward both shorter employment terms and slimmer benefits. "Legally, these companies aren't permitted to influence the delivery of services, but in general, they're non-physician companies, which means that the MBAs are making contract decisions, not physicians," said Ms. Gwilt, who frequently speaks on physician contract

Career Resources articles posted on NEJM CareerCenter are produced by freelance health care writers as an advertising service of NEJM Group, a division of the Massachusetts Medical Society, and should not be construed as coming from the *New England Journal of Medicine*, nor do they represent the views of the *New England Journal of Medicine* or the Massachusetts Medical Society.

issues. “So, as this [model] becomes more common, market salaries and benefits could change.”

Although the trend toward super-group formation isn’t inherently negative — such groups have more bargaining power regarding physicians’ reimbursement rates than smaller ones do, generally — it does call for due diligence and research on the part of physicians who consider interviewing with such entities. “You first should find out who runs the company, because you will have less room to negotiate a contract than with a physician-owned practice,” Ms. Gwilt said. “You want to know what it’s like to work there, so I advise clients to ask for the name of the last physician hired — someone who’s been there for a year — and then talk to that physician.”

The movement toward “corporatization” of medicine, in tandem with the fluctuating health care economic, reimbursement, and policy environment, is prompting employers to reduce their financial risk wherever possible. One example is instituting shorter contract employment terms, which enables employers to more easily let go of poor-performing physicians. Another recent development is the setting of limits on how much individual physicians can earn, regardless of their productivity, according to Kyle Claussen, CEO of Resolve Physician Agency, a Missouri-based firm that counsels physicians on contract issues.

“It’s becoming more prevalent to see clauses with caps on compensation, such as the 75th or 90th percentile in a major national survey such as the Medical Group Management Association survey,” Mr. Claussen said. Although such caps aren’t likely to affect most physicians coming out of residency because starting salaries are rarely set at those percentiles, the caps could penalize high-income specialties such as neurosurgery and orthopedic surgery as those physicians move into their second and third years of practice. “I’ve seen some high-income specialists walk away from those potential jobs,” he said. He added — and other sources concurred — that sign-on bonuses are less common now than they were a few years ago, possibly for some of the same economic reasons.

Another contract area where shifts are occurring involves bonuses and productivity-based compensation, several sources mentioned. As employers, as well as government and commercial insurers, move toward providing monetary incentives to physicians for performance on measures ranging from patient satisfaction to hospital readmissions, it’s important to know how such payments are handled on the employer side. This is particularly

the case with any bonuses or incentive payments that may be due a physician, Mr. Schaff pointed out.

For example, if the contract states that incentives and bonuses are paid only through the employment period or only at the end of a calendar year, the physician might lose out on a substantial sum if he or she leaves the job on, say, Dec. 22, rather than Jan. 1 of the following year. Ideally, the contract should call for payment of “all bonuses earned through the time of termination.”

Ditto for accounts receivable monies that physicians might be due. It’s very common for such monies to continue flowing to the practice for several months after a physician departs, so ideally, Mr. Schaff suggested, the contract should call for reporting on such funds for a specific period after termination and ultimately paying out what’s due at, say, 60, 90, or even 180 days post-termination of employment. “This is all over the map in contracts I’ve seen,” Mr. Schaff said. “I’ve even seen contracts that state that the physician only receives payments through the last day of employment. This is something that should be negotiated.”

At the other end of the spectrum, physicians whose contracts set minimum or expected productivity or quality performance targets in order to continue the base salary beyond year one should understand not only what those requirements are but also — and more importantly — whether they’re achievable and reasonable. That means talking to other physicians at the prospective practice to see how they’ve fared in year two in productivity. It’s also helpful to find out how much personal effort is required to track the performance metrics that underlie performance payments, several sources advised. Mr. Mayer said that when a base salary arrangement converts to a totally productivity-based one at the end of the first year, he often negotiates for something less dramatic, such as continuation of the base salary for an extended period or perhaps a part-base/part-productivity structure.

“The point is that your contract governs how your money works, and compensation structures are becoming increasingly complicated,” Ms. Gwilt said. “That’s why it’s really important that physicians understand those structures and obtain legal review.” It’s not uncommon for compensation methodologies to incorporate a half-dozen components beyond base salary, such as incentive bonuses or “clawbacks” (monies returned to the employer for underperformance or other reasons) based on quality measures, cost metrics, patient-specific clinical measure reporting, compliance, and shared savings, to name a handful.

On a final note, all sources stressed the importance of physicians reading every word of the contract and obtaining expert review. The point is to make sure that physicians understand what the contract entails and what its provisions would look like in their daily lives, by requesting specific examples of not only what's expected of them but also what might happen should they leave the position prematurely. "One thing that physicians need to think about but are reluctant to ask is this: What happens if they want to get out or if the employer wants to terminate the contract?" Ms. Gwilt said. "If there's a penalty clause, that should be highly negotiated."

Contract pitfalls to watch for


Contract language that's vague and highly employer-favorable. Such language might show up in any area of the contract, but it's especially problematic when it comes to physician schedules and duties, according to Ms. Gwilt. "You want to beware of anything that states, 'X will be determined by the practice at its discretion,'" she said. That leaves the physician open to whatever the employer decides at any time during the contract period. At the least, physicians should negotiate to add that the terms be "fair and reasonable, and in accordance with [requirements] for all like colleagues."

Mr. Mayer provides an example of where "at the practice's discretion" could have a serious lifestyle effect: unspecified practice locations. As organizations merge and/or add satellite facilities, a vague location clause might mean that physicians could be required to commute to or travel among four different clinics or hospitals. Mr. Mayer suggests that physicians ask prospective employers to specify locations and limit their number contractually, or at least give the physician the opportunity to decide if she or he is willing to expand the number.

Highly restrictive non-compete clauses. Syracuse, New York, attorney Andrew Knoll, JD, MD, cautions physicians to beware of and negotiate onerous non-compete terms when employers aim to keep physicians from working for a slew of specific competitors. "I've seen clauses that state, 'Within two years of leaving the practice, the physician cannot work for health system Y or hospitals A, B, or C.' That's overly broad. Others might restrict the employee from going to a particular large health system, but not to smaller hospitals or systems in the same urban area," Mr. Knoll said. "These clauses should always be reviewed."

Unreasonable benefit start dates. One pitfall with benefits is not ensuring that they commence at a reasonable time, Mr. Schaff observed. For example, if a contract stipulates that health insurance benefits start on the first day of the month following hiring or 90 days hence, he said, "The physician could be on the hook for paying the premiums for COBRA [continued coverage from the previous employer]. At the least, if the benefits start date can't be modified, the incoming physician might try to negotiate that the employer pay the COBRA premiums until the coverage starts."

Onerous — or unspecific — indemnification or liquid damages clauses, especially regarding malpractice claims. The first order of business here is to understand any limitations that employer-paid malpractice coverage might have, and then ensure that the employed or contracted physician isn't on the hook fully for additional damages that the policy doesn't cover, Mr. Mayer advised. For example, if the malpractice coverage tops out at \$1 million and the judgment comes in at \$1.25 million, some contracts might shift the entire shortfall to the physician, explicitly or not so explicitly. "Such a provision might say that 'the practice and the doctor agree to indemnify and hold each other harmless for any liability caused by the other,'" Mr. Mayer said. "It sounds and seems fair, but in practice, the malpractice claim will usually follow the physician, not the practice. This is something that requires careful review and possibly negotiation."

 Did you find this article helpful? Sign up for our Career Resources Update e-newsletter to get more physician career articles delivered right to your inbox! www.nejmcareercenter.org/register.

CLINICAL PRACTICE

Caren G. Solomon, M.D., M.P.H., *Editor*

Postmenopausal Osteoporosis

Marcella Donovan Walker, M.D., and Elizabeth Shane, M.D.

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the authors' clinical recommendations.

From the Division of Endocrinology, Department of Medicine, Columbia University Irving Medical Center, New York. Dr. Shane can be contacted at es54@cumc.columbia.edu or at Columbia University Irving Medical Center, 180 Fort Washington Ave., Harkness Pavilion, Rm. 9-910, New York, NY 10032.

N Engl J Med 2023;389:1979-91.

DOI: 10.1056/NEJMc2307353

Copyright © 2023 Massachusetts Medical Society.

CME
at NEJM.org

A 69-year-old woman presents to review the results of her first dual-energy x-ray absorptiometry (DXA) scan. Her T scores are –2.6 at the lumbar spine and –2.3 at the total hip. She fell while walking 18 months ago and fractured her left humerus. Imaging of the spine, performed to investigate 5 cm (2 in.) of height loss and moderate thoracic kyphosis, reveals two vertebral fractures. How should this patient be evaluated and treated?

THE CLINICAL PROBLEM

POSTMENOPAUSAL OSTEOPOROSIS IS CAUSED BY ESTROGEN DEFICIENCY, which leads to increased osteoclast differentiation and activation, accelerated bone resorption that outpaces formation, and rapid bone loss, particularly in the years immediately before and after menopause. This results in low bone mineral density, deteriorated bone microarchitecture, decreased bone strength, and increased risk of fragility fractures. Postmenopausal osteoporosis is diagnosed on the basis of the occurrence of a fragility fracture (with no associated trauma or with trauma equivalent to falling from a standing height or less) or bone mineral density at the spine, total hip, or femoral neck that is at least 2.5 standard deviations below the mean of that in a young adult reference population (T score of –2.5 or less), as measured with the use of DXA. In the United States, approximately 20% of women over 50 years of age and 30% of women 65 years of age or older meet DXA criteria for osteoporosis.^{1,2} In the United States, osteoporosis is more common among White, Asian, and Hispanic women than among non-Hispanic Black women.² An additional 40% of postmenopausal women have low bone mass (osteopenia; defined as a T score between –1.0 and –2.49). Approximately 50% of postmenopausal women will have fragility fractures, which cause pain, disability, and decreased quality of life. After a hip fracture, many women never regain independence, 20% are institutionalized, and the risk of death within 1 year doubles.^{3,4} Non-White women who have hip fractures are more likely to die within 6 months, are less likely to regain independence, and have less timely surgery and rehabilitation than White women who have hip fractures.⁵ The annual health care cost associated with fractures related to postmenopausal osteoporosis in the United States, currently \$57 billion, is projected to exceed \$95 billion by 2040.⁶

STRATEGIES AND EVIDENCE

DIAGNOSIS AND EVALUATION

Osteoporosis is asymptomatic until the first clinical fracture. Bone mineral density as measured with the use of DXA is the gold standard for identifying patients at risk. Each standard deviation reduction below a T score of 0 is associated with

KEY CLINICAL POINTS

POSTMENOPAUSAL OSTEOPOROSIS

- Fragility fractures are very common among postmenopausal women and are associated with increased morbidity, mortality, and health care expenditures.
- Dual-energy x-ray absorptiometry (DXA) is recommended in postmenopausal women 65 years of age or older and postmenopausal women younger than 65 years of age who have risk factors.
- Osteoporosis is diagnosed on the basis of a fragility fracture or a DXA T score of –2.5 or less.
- Treatment of postmenopausal osteoporosis is recommended for patients who have any of the following findings: a fragility fracture (or fractures), particularly of the hip or spine, regardless of the patient's bone mineral density; a T score of –2.5 or less at the lumbar spine, total hip, or femoral neck; or a high 10-year fracture risk (hip fracture risk of $\geq 3\%$ or major osteoporotic fracture risk of $\geq 20\%$) according to the fracture risk assessment tool (FRAX).
- Evaluation should include risk stratification (based on the T score, presence of fractures, and FRAX score) to categorize candidates who meet treatment thresholds as “high risk” or “very high risk.”
- The selection of therapy must include consideration of coexisting conditions and contraindications, but anabolic agents are the preferred first line of treatment in women at very high risk.

a doubling or tripling in the risk of fracture.⁷ Most guidelines recommend DXA of the spine and hip for postmenopausal women 65 years of age or older and for postmenopausal women younger than 65 who have risk factors (Table 1).⁸⁻¹¹ Forearm bone mineral density predicts fracture and can be measured if recommended sites are not evaluable or if hyperparathyroidism is present. Fragility fractures of the spine, hip, forearm, humerus, and pelvis are diagnostic of osteoporosis, even with T scores higher than –2.5. The occurrence of a fragility fracture is associated with a marked increased in the imminent risk of additional fractures.¹²

Vertebral compression fractures, the most common osteoporotic fractures, are frequently painful and cause height loss but may be asymptomatic. Vertebral fractures are associated with increased mortality, and the presence of vertebral fractures influences diagnosis, risk stratification, and therapeutic decisions.¹³ Vertebral fracture analysis, a low-radiation spine image obtained on a densitometer when bone mineral density is measured, has high sensitivity and specificity to detect moderate or severe ($\geq 25\%$) vertebral compressions. Vertebral fracture analysis or spine radiography should be performed when suspicion is high (e.g., height loss of >1.5 inches [>3.8 cm]) or if the management strategy may be affected (Fig. 1). Fracture risk can be estimated with the use of the fracture risk assessment tool (FRAX) or other validated calculators. FRAX estimates the 10-year probability of major osteoporotic fracture and hip fracture on

the basis of clinical risk factors (Table 1), with or without a measurement of bone mineral density. Many authorities recommend designating patients who have an elevated fracture risk but do not have T scores of –2.5 or less or a fragility fracture as having osteoporosis.¹⁴

Bone microarchitecture contributes to bone strength and can be assessed by means of several methods. The trabecular bone score — a Food and Drug Administration (FDA)–cleared, Medicare-covered, indirect measure of spine trabecular microarchitecture that is obtained from a DXA image with the use of additional commercially available software — predicts fracture risk independent of bone mineral density.¹⁵ FRAX-estimated fracture risk or T scores can be adjusted with the use of the trabecular bone score to enhance risk stratification. The trabecular bone score is most useful when it influences treatment decisions (e.g., for osteopenia or when the level of fracture risk is close to an intervention threshold) but should not be used alone for diagnosis. FDA-approved, clinically available software now permits opportunistic screening of volumetric bone mineral density, bone strength, and prevalent vertebral fractures with the use of routine clinical computed tomography (CT) to identify persons at risk for future fractures. Evidence suggests that this technology performs at least as well as DXA. Measurement of bone microstructure and strength by means of high-resolution peripheral quantitative CT (HRpQCT) predicts fracture risk independent of bone mineral density but is not FDA-approved for diagnosis.¹⁶

OTHER EVALUATIONS

Medical history, medications, and risk factors should be assessed. Other metabolic bone diseases that are associated with low bone mineral density, such as osteomalacia, are important diagnostic considerations (Fig. 1). Conditions (e.g., celiac disease) and medications (e.g., glucocorticoids) that cause remediable bone loss should be addressed (Table 1). Because there is no consensus regarding the most cost-effective laboratory evaluation, testing depends on the clinical situation but must, at minimum, identify contraindications to specific therapeutics (Fig. 1 and Table 2).

TREATMENT

The fundamental goal of treatment is to prevent fractures in women at high risk before their first fracture (primary prevention) or before a subsequent fracture (secondary prevention). Lifestyle modifications are applicable to all of these patients. Pharmacologic interventions (Table 2) are targeted to women at high risk for fracture. Intervention thresholds vary according to different guidelines (Table 3), but many guidelines recommend treating women who have fragility fractures of the hip or spine, regardless of bone mineral density; those with T scores of -2.5 or less at the lumbar spine, total hip, or femoral neck; and those with high 10-year fracture risk as assessed with the use of FRAX (hip fracture risk of $\geq 3\%$ or major osteoporotic fracture risk of $\geq 20\%$).⁸ Findings from randomized, controlled trials support the fracture-risk–reduction efficacy of FDA-approved treatments based on T scores or fracture criteria (or both). Evidence that supports treatment based on FRAX-estimated fracture risk is less robust.^{8,25,26}

LIFESTYLE CHANGES

Patients should be encouraged to stop smoking, avoid excessive alcohol, increase weight-bearing exercise, and prevent falls.^{27,28} Most guidelines recommend 1000 to 1200 mg of calcium daily in women with postmenopausal osteoporosis, preferably obtained from diet,^{8,11} and 400 to 1000 IU of vitamin D daily.^{8,11} Some experts and guidelines recommend adjusting vitamin D intake to achieve serum 25-hydroxyvitamin D levels higher than 20 to 30 ng per milliliter, but this ap-

Table 1. Risk Factors for Postmenopausal Osteoporosis and Fracture.


Older age
Low weight (<127 lb [<58 kg])
Previous fracture during adulthood (particularly hip, spine, or wrist); recent fracture indicates a higher risk than remote or unclear history
Parental history of hip fracture
Current or past glucocorticoid treatment (>5 mg prednisolone daily or equivalent for 3 mo or more)
Other medications that cause bone loss*
Current smoking
Excess alcohol intake
Causes of secondary osteoporosis†
Rheumatoid arthritis
Premature menopause (<40 yr of age) or hypogonadism
Frequent falls

* These medications include (but are not limited to) aromatase inhibitors, suppressive doses of thyroid hormone, chemotherapy, cyclosporine, unfractionated and low-molecular-weight heparins, antidepressants, thiazolidinediones, selected anticonvulsant drugs, and proton-pump inhibitors. Some drug categories have been associated with higher fractures in epidemiologic studies but have not been causally linked.

† Causes include (but are not limited to) organ transplantation, primary hyperparathyroidism, chronic kidney disease, type 1 and type 2 diabetes, anorexia nervosa, hypopituitarism, malabsorption, bariatric surgery, immobility, untreated hyperthyroidism, chronic pulmonary disease, human immunodeficiency virus infection, Cushing's disease, osteogenesis imperfecta, Gaucher's disease, and Marfan syndrome.

proach is controversial and not supported by rigorous data.^{8,24}

Whether calcium and vitamin D supplementation reduces fractures remains debated. Limited evidence suggests supplemental calcium combined with vitamin D significantly reduces hip fractures, but not nonvertebral or vertebral fractures, in patients with postmenopausal osteoporosis.¹⁷ Because the efficacy of most osteoporosis medications has been studied in conjunction with calcium and vitamin D supplementation, and some osteoporosis medications can cause hypocalcemia, adequate calcium and vitamin D intake is prudent. Risks associated with calcium supplementation include nephrolithiasis and, according to some meta-analyses, increased incidence of cardiovascular events, although studies



included in the meta-analyses were not designed to assess cardiovascular outcomes.²⁹

PHARMACOLOGIC APPROACHES

Therapies for postmenopausal osteoporosis act by reducing bone resorption (antiresorptive therapies), stimulating bone formation (anabolic

therapies), or both. All pharmacologic approaches reduce vertebral fracture risk, and some reduce the risk of nonvertebral and hip fractures.¹⁷ Table 2 summarizes available therapies and fracture risk reductions that have been assessed in randomized, controlled trials. Selection of a therapy must include the consideration of osteo-

Figure 1 (previous page). Diagnostic Algorithm for the Evaluation of Postmenopausal Osteoporosis.

The evaluation of skeletal health in postmenopausal women starts with a history focusing on previous fractures and clinical risk factors for osteoporosis and fractures. A physical examination should evaluate for significant kyphosis and height loss, which if present should prompt imaging of the spine. A fragility fracture (particularly of the spine, hip, wrist, humerus, or pelvis) is diagnostic of osteoporosis. Women 65 years of age or older, regardless of other risk factors, and women younger than 65 years of age who have risk factors for bone loss or fractures should undergo dual-energy x-ray absorptiometry (DXA) screening. The timing of spine imaging may occur before, coincident with, or after DXA. If software is available to assess a trabecular bone score (TBS), the score can be obtained with a measurement of bone mineral density for fracture risk stratification in women with low bone mass (osteopenia). A T score of -2.5 or less is consistent with osteoporosis. T scores of -1.0 to -2.49 are consistent with osteopenia or low bone mass. The fracture risk assessment tool (FRAX) can be used with or without DXA and TBS to estimate a 10-year probability of major osteoporotic fracture (MOF) and hip fracture. MOF risk of 20% or more or hip fracture risk of 3% or more is consistent with osteoporosis in the absence of a fragility fracture even if the T score is above -2.5 . DXA can be obtained in women with a fragility fracture and used to monitor effectiveness of treatment but is not necessary for diagnosis. Laboratory evaluation should exclude contraindications to treatments. Additional laboratory evaluations and studies may be appropriate depending on the clinical situation; a complete blood count (CBC) should be performed to evaluate for myeloma, if results are not already available. Alternative diagnoses (e.g., drug-induced osteoporosis, osteomalacia, primary hyperparathyroidism, cancer, and chronic kidney disease–mineral and bone disorder [CKD-MBD]) should be considered and addressed on the basis of clinical and laboratory information. Treatment of postmenopausal osteoporosis should be initiated if there are no contraindications. 25 OH vitamin D denotes 25-hydroxyvitamin D, ESR erythrocyte sedimentation rate, PTH parathyroid hormone, SPEP serum protein electrophoresis, TSH thyrotropin, and UPEP urine protein electrophoresis.

porosis severity, fracture risk, coexisting conditions, and factors and preferences specific to the patient. “High risk” for fracture is typically defined as meeting the minimal intervention thresholds. “Very high risk” is typically defined as having a T score of less than -3.0 , a fragility fracture and a T score of -2.5 or less, or multiple vertebral fractures. Most guidelines suggest initial treatment with anabolic agents in women at very high risk, unless contraindicated (Table 3).

Bisphosphonates

For women with postmenopausal osteoporosis who are at high risk for fracture, most guidelines recommend bisphosphonates as initial treatment, given their efficacy, safety, convenience, low cost, and enduring effects after discontinuation (Table 2). Four oral and intravenous bisphosphonates are FDA-approved for postmenopausal osteoporosis. All reduce the risk of vertebral fracture.²⁴ All but ibandronate reduce the risk of hip and nonvertebral fractures.^{17,24} When administered within 90 days after hip fracture repair and annually for 3 years, zoledronate also reduced the risk of death, although the mechanism is unclear.

Oral bisphosphonates are poorly absorbed and may cause upper gastrointestinal mucosal irritation (Table 2). Intravenous zoledronate is preferred in patients who have this side effect and those with esophageal dysfunction. Acute-phase reactions may occur with zoledronate but can be mitigated with preinfusion and postinfusion oral hydration and acetaminophen. Long-term use of bisphosphonates has been associated with osteonecrosis of the jaw and atypical femur fractures. Osteonecrosis of the jaw is an area of exposed jaw bone that does not heal within 8 weeks after identification by a health care provider.¹⁹ Atypical femur fractures are low-trauma subtrochanteric or femoral-shaft fractures with specific radiographic criteria.²² In patients receiving bisphosphonates at doses used for postmenopausal osteoporosis, the estimated risks of osteonecrosis of the jaw and atypical femur fracture are very low.

Denosumab

In randomized, controlled trials conducted over a period of 3 years, denosumab lowered the risk of spine, hip, and nonvertebral fractures as compared with placebo.¹⁷ In long-term, open-label extension studies, the lower risk of fractures was maintained.³⁰ Although gains in bone mineral density are greater with denosumab than with bisphosphonates, evidence for greater reduction of fracture risk is limited.³¹ Denosumab is also rarely associated with osteonecrosis of the jaw and atypical femur fracture³⁰ and with hypocalcemia in patients with advanced chronic (stage 4 or 5) kidney disease or vitamin D deficiency (Table 2).

Table 2. Pharmacologic Therapies for Postmenopausal Osteoporosis.*

Drug Class and Medication	Mechanism of Action	Treatment Dose	Fracture Risk Reduction ^{17,18,†}		Adverse Effects	Contraindications and Warnings
			Vertebral	Non-vertebral		
			percent			
Antiresorptives						
Bisphosphonates	Bind to bone hydroxyapatite, engulfed by osteoclasts, and inhibit bone resorption					
Alendronate‡		10 mg once daily or 70 mg once weekly orally	44	17	GI irritation, MSK pain; rarely ONJ, AFF‡§	Esophageal varices or dysmotility, creatinine clearance <30 – 35 ml per min, hypocalcemia, bisphosphonate allergy
Risedronate‡		5 mg daily, 35 mg weekly, or 150 mg monthly orally	36	20	Same as for alendronate	Same as for alendronate
Ibandronate‡¶		2.5 mg daily or 150 mg monthly orally, or 3 mg every 3 mo IV	31	ND	Same as for alendronate	Same as for alendronate
Zoledronic acid¶		5 mg per yr IV	56	18	Acute-phase reaction, renal impairment, hypocalcemia, atrial fibrillation, rarely ONJ and AFF‡§	Creatinine clearance <35 ml per min, AKI, hypocalcemia, bisphosphonate allergy; important to ensure vitamin D sufficiency
RANK ligand inhibitor — denosumab	Human monoclonal antibody that binds RANKL; inhibits osteoclast formation, function, and survival	60 mg every 6 mo subcutaneously	68	20	MSK pain, skin infections, rashes, hypocalcemia, rarely ONJ and AFF‡§; rebound bone loss and fractures after stopping	Hypocalcemia, hypersensitivity; important to ensure vitamin D sufficiency
Estrogens — CEE¶¶	Decreases osteoclastic bone resorption	0.625 mg daily orally	34	21	CEE alone; stroke; CEE plus medroxyprogesterone: stroke, CHD, breast cancer, dementia, thromboembolic events	History of breast cancer, CHD, VTE, stroke, TIA; active liver disease; unexplained vaginal bleeding; increased risk of endometrial cancer

SERMs (e.g., raloxifene)**	Weak estrogen agonist activity in bone, decreases osteoclastic bone resorption	Raloxifene 60 mg daily orally	40	ND	ND	VTE, hot flashes, night sweats, peripheral edema, leg cramps, increased risk of death from stroke	History of VTE, PE, retinal vein thrombosis
Anabolic agents, PTH receptor agonists							
PTH analogue — teriparatide (PTH 1-34)	Increases bone formation	20 µg daily subcutaneously	74	ND	39	Hypercalcemia, muscle cramps, nausea, headache, dizziness, hypotension	Bone metastases, skeletal cancers, history of skeletal radiation, increased risk of osteosarcoma, Paget's disease, hypercalcemic disorders, unexplained elevated alkaline phosphatase, hypersensitivity
PTH-rP analogue — abaloparatide (PTHrP 1-34)	Increases bone formation	80 µg daily subcutaneously	87	ND	46	Same as for teriparatide (PTH 1-34)	Same as for teriparatide (PTH 1-34)
Anabolic-antiresorptive agent							
Sclerostin inhibitor — romosozumab	Human monoclonal antibody against sclerostin; increases bone formation, decreases bone resorption	210 mg per mo subcutaneously	73	38††	19††	Arthralgia, headache, MSK pain, hypocalcemia, CV events; rarely ONJ, AFF	Recent stroke or MI; other CV risks; hypocalcemia, or hypersensitivity; important to ensure vitamin D sufficiency

* AFF denotes atypical femoral fracture, AKI acute kidney injury, CEE conjugated equine estrogen, CHD coronary heart disease, CV cardiovascular, GI gastrointestinal, HRT hormone replacement therapy, IV intravenous, MI myocardial infarction, MSK musculoskeletal, ND not demonstrated, ONJ osteonecrosis of the jaw, PE pulmonary embolism, PTH parathyroid hormone, RANKL receptor activator of nuclear factor κB ligand, SERM selective estrogen-receptor modulator, TIA transient ischemic attack, and VTE venous thromboembolism.

† Reduction shown is as compared with placebo in randomized, controlled trials and meta-analyses and not in head-to-head comparisons.

‡ Patients should be instructed to take oral bisphosphonates with 6 to 8 oz of plain water at least 30 min before the first food, drink, or medication of the day and avoid lying down for at least 30 min after taking the bisphosphonate.

§ ONJ has been reported at a rate of 1 to 69 per 100,000 person-yr and 0 to 90 per 100,000 person-yr with oral and IV bisphosphonates, respectively. AFF has been reported at a rate of 1.78 per 100,000 person-yr with less than 2 yr of bisphosphonates, increasing to 113.1 per 100,000 person-yr after 8 to 10 yr.¹⁹ The risk of AFF may be higher among Asian women than among White women.²⁰

¶ Acute-phase reactions can be mitigated with preinfusion and postinfusion oral hydration and acetaminophen.

|| Estrogen is approved for the prevention of postmenopausal osteoporosis.

** Bazedoxifene (20 mg) in combination with conjugated estrogen (0.45 mg), taken once daily, is approved for prevention of postmenopausal osteoporosis.

†† Vertebral and nonvertebral risk reductions are only as compared with alendronate in the ARCH trial²¹ and not as compared with placebo in the FRAME trial.¹⁸

Table 3. Intervention and Treatment Guidelines.*

Guideline	Intervention Threshold	Initial Treatment	Duration
AACE-ACE 2020 ¹¹	T score of -2.5 or less at the spine, femoral neck, total hip, or 33% radius; osteopenia (T score, -1.00 to -2.49) and history of fragility fracture of the hip or spine; osteopenia and high probability of fracture as estimated with the use of FRAX	Alendronate, denosumab, risedronate, zoledronate†; ibandronate or raloxifene are alternatives for spine-specific therapy only ²²	Very High Risk of Fracture†
American College of Physicians 2023 ¹⁰	T score of -2.5 or less; individualize in those >65 yr of age with osteopenia	Bisphosphonates; denosumab if contraindications to bisphosphonates	Oral bisphosphonates ²² — treat for 5 yr, then consider holiday if fracture risk is no longer high; if fracture risk remains high, continue treatment for up to an additional 5 yr; in patients at very high risk, consider holiday after 6–10 yr of stable BMD; zoledronic acid ²² — consider holiday after 3 yr of high risk or until fracture risk is no longer high, continue for 6 years in patients at very high risk; holiday not recommended for non-bisphosphonate antiresorptive therapies; abaloparatide or teriparatide — treat for 2 yr, then follow with antiresorptives; romosozumab — treat for 1 yr, then follow with antiresorptives ²²
Bone Health and Osteoporosis Foundation ⁸	T score of -2.5 or less at the femoral neck, total hip, lumbar spine, 33% radius¶; fracture of the hip or vertebra regardless of BMD by DXA; osteopenia at the femoral neck or total hip by DXA with 10-yr hip fracture risk ≥3% or MOF risk ≥20% by FRAX; osteopenia with fracture of proximal humerus, pelvis, or distal forearm; individualized approach for those with proximal humerus, pelvis, or distal forearm fractures without osteopenia	Teriparatide or romosozumab followed by antiresorptives§	Bisphosphonate use for >3–5 yr reduces vertebral fracture but not other fractures, with increased risk of long-term harms; consider stopping after 5 yr unless strong indication to continue
	Generally follows Endocrine Society algorithm	Teriparatide or romosozumab followed by antiresorptives§	Oral and IV bisphosphonates — treat for 5 yr and (e.g., T score greater than -2.5 and no recent fracture), consider holiday; for patients who remain at high fracture risk (e.g., T score of -2.5 or less or recent fracture or both), consider alternative treatment or continued treatment with a bisphosphonate for ≤10 yr (oral) or ≤6 yr (annual IV zoledronic acid) ²²

<p>Endocrine Society 2019–2020^{23,24}</p> <p>Postmenopausal women at high risk of fractures, especially those with a recent fracture</p>	<p>Bisphosphonates: alternative therapy is denosumab; SERMs, ET, and calcitonin recommended in specific groups only^{**}</p>	<p>Teriparatide or abaloparatide; romosozumab if not at high CV risk</p>	<p>Bisphosphonates — reassess fracture risk in 3 yr (IV) or 5 yr (oral); if high risk, continue therapy or begin alternative therapy; if low to moderate risk, consider holiday up to 5 yr but reassess every 2–4 yr^{††}; denosumab — reassess fracture risk after 5–10 yr; women remaining at high risk should continue denosumab or be treated with other therapies; abaloparatide or teriparatide — treat for 2 yr, then follow with antiresorptives; romosozumab — treat for 1 yr, then follow with antiresorptives</p>
<p>ESCEO and IOF⁹</p> <p>Women >65 yr of age with a previous fragility fracture and those without a previous fracture who have an age-specific probability of fragility fracture that is equal to that of women with a previous fragility fracture^{††}</p>	<p>Oral bisphosphonates; IV bisphosphonates or denosumab are the most appropriate alternatives with contraindications to or adverse effects from oral bisphosphonates; raloxifene and HRT are also options</p>	<p>Teriparatide is preferentially recommended</p>	<p>Bisphosphonate treatment should be reviewed after 3–5 yr; bisphosphonates should be used after discontinuation of denosumab; little evidence to guide decision making beyond 10 yr; treatment decisions should be individualized</p>

* AACE denotes American Association of Clinical Endocrinology, ACE American College of Endocrinology, BMD bone mineral density, DXA dual-energy x-ray absorptiometry, ESCEO European Society for Clinical and Economic Aspects of Osteoporosis, ET estrogen therapy, FRAX fracture risk assessment tool, HRT hormone replacement therapy, IOF International Osteoporosis Foundation, MOF major osteoporotic fracture, and SERMs selective estrogen-receptor modulators.

† Very high risk is variably defined but is often used to describe patients with a T score of less than -3.0, spine or hip fracture and T score of -2.5 or less at the lumbar spine or hip, or multiple spine or fragility fractures. Some guidelines include in this category patients who have had a fracture within the previous 12 months, fracture occurring during therapy, fracture while receiving drugs causing bone loss (e.g., long-term glucocorticoid therapy), high risk of falling, and very high fracture probability according to FRAX scale (e.g., major osteoporosis fracture >30%, hip fracture >4.5%, or age).

†† The AACE-ACE guidelines list the drugs in alphabetical order and not in sequence of the most appropriate therapy.

‡ Abaloparatide and SERMs are not recommended by the American College of Physicians, which regards the evidence as inconclusive to recommend for or against use of these agents.

§ On the basis of existing data, there is less certainty regarding the use of a T score of -2.5 or less at the 33% radius site as a threshold for treatment.

|| Ibandronate is not recommended to reduce the risk of hip fracture.

** SERMs are recommended in patients at low risk of DVT when bisphosphonates or denosumab are not appropriate or if there is a high risk of breast cancer. HRT is recommended in women who are younger than 60 years of age or less than 10 years past menopause, who are at low risk of DVT, and in whom bisphosphonates and denosumab are not appropriate. Calcitonin is only recommended if adverse effects result with the use of SERMs, bisphosphonates, estrogen, denosumab, PTH analogues, and other therapies.

†† Consider reinitiating osteoporosis therapy earlier than the 5-year suggested maximum if there is a clinically significant decline in BMD, an incident fracture, or other factors that alter the clinical risk status.²²

‡‡ Probability and intervention thresholds vary by country, health system, and willingness to pay.

Although denosumab is an alternative treatment option for women at high risk for fracture who have contraindications to bisphosphonates or cannot take them owing to unacceptable adverse effects, there is concern about accelerated bone resorption and rapid bone loss after discontinuation of denosumab therapy. Whether denosumab should be used as initial therapy in women who are at high risk — but not at very high risk — for fracture who have other treatment options is debated among some experts. In a post hoc analysis of a trial that compared denosumab with placebo, the incidence of vertebral fractures increased from 1.2 to 7.1 per 100 participant-years after treatment with denosumab was discontinued, a finding similar to that observed after discontinuation of placebo, but the incidence of multiple vertebral fractures was higher after discontinuing denosumab than after discontinuing placebo (3.4% vs. 2.2%).³² Therefore, patients must continue denosumab therapy indefinitely or transition to treatment with bisphosphonates to maintain bone mineral density and prevent incident vertebral fractures.

Weekly administration of alendronate, initiated 6 months after receipt of the last dose of denosumab, may prevent bone loss.³³ The efficacy of zoledronate may depend on the timing and frequency of administration.³⁴ Some experts recommend administering zoledronate 6 to 7 months after the last dose of denosumab, with another dose 3 to 6 months later, depending on bone-turnover markers.³⁵ Administering denosumab on time every 6 months is also important. Retrospective data show that administering denosumab late (>16 weeks' delay) was associated with an incidence of vertebral fractures that was nearly four times as high as that seen among patients who received denosumab doses on time (≤4 weeks' delay).³⁶

PTH Receptor Agonists

Parathyroid hormone (PTH) receptor agonists include teriparatide (PTH 1-34) and abaloparatide (PTHrP 1-34). As compared with placebo, treatment for 18 to 24 months with teriparatide or abaloparatide reduces vertebral and nonvertebral fracture risk.¹⁷ Neither drug has been shown to reduce the incidence of hip fractures, but studies were underpowered for this outcome.³⁷ Both agonists require daily injections. Antire-

sorptive therapy is indicated after PTH receptor agonist therapy is complete and increases bone mineral density further; without it, bone mineral density decreases within a year.³⁸

Most guidelines limit the use of PTH receptor agonists to patients at very high risk for fracture or to patients who have unacceptable side effects with or are unresponsive to other therapies (Table 3). Although both agents increase bone mineral density of the spine to a similar degree, an open-label comparison suggested greater increases in bone mineral density of the hip with abaloparatide.³⁹ Limited trial data indicate that teriparatide increases bone mineral density of the spine more than alendronate and decreases vertebral fractures more than risedronate, findings that support its use in patients at very high risk for fractures.^{40,41}

Because studies in rodents showed that teriparatide increased the incidence of osteosarcoma, the original FDA package labeling included a black-box warning and limited treatment to 2 years. Recent data show that the incidence of osteosarcoma among patients who are treated with teriparatide is similar to the background incidence of the disease.⁴² Although the FDA removed the time limitations for treatment with some PTH receptor agonists, limited safety and efficacy data exist for treatment of longer durations. These agents should be avoided in patients at increased risk for osteosarcoma (e.g., patients with Paget's disease or skeletal irradiation). Longer durations or repeated courses of treatment may be appropriate in patients whose risk of fracture remains at or returns to high or very high levels or who do not have a response to other therapies.

Romosozumab

Romosozumab, given monthly as subcutaneous injections, is the newest FDA-approved therapeutic for postmenopausal osteoporosis. In a phase 2 study, romosozumab increased bone mineral density more than teriparatide.⁴³ In the Fracture Study in Postmenopausal Women with Osteoporosis (FRAME), romosozumab reduced the risk of vertebral and clinical (composite symptomatic vertebral and nonvertebral) fractures at 12 months as compared with placebo.¹⁸ The risk of vertebral fracture remained lower in the romosozumab group after 1 year of treatment with denosumab.

Similar to treatment with PTH receptor agonists, romosozumab therapy must be followed by treatment with bisphosphonates or denosumab.¹⁸ In another trial that investigated treatment with romosozumab as compared with alendronate for 1 year, both followed by alendronate for 1 year,²¹ romosozumab reduced vertebral, nonvertebral, and hip fractures more than alendronate. Although not observed in FRAME, a higher incidence of serious cardiovascular events with romosozumab (2.5% vs. 1.9%) led to a black-box warning against the use of romosozumab within 1 year after myocardial infarction or stroke. Many guidelines recommend romosozumab as initial therapy only for persons at very high risk for fracture, with use limited to 1 year (Table 3).

Other Antiresorptive Agents

Owing to adverse effects, estrogen therapy and selective estrogen-receptor modulators are recommended only in selected populations or circumstances (Table 3). Calcitonin, a weak antiresorptive agent, is rarely used for postmenopausal osteoporosis.

Combination Treatment

Concurrent treatment with teriparatide and bisphosphonates has no added benefit with respect to the bone mineral density of the spine and hip as compared with teriparatide alone.⁴¹ The combination of denosumab and teriparatide increases bone mineral density of the hip and spine more than either alone, but is not endorsed by guidelines or routinely covered by insurance.⁴⁴

MONITORING

Most guidelines suggest repeating DXA 1 to 2 years after initiating or changing therapy, but from there recommendations diverge.^{8,11,24} Non-response, defined as a decrease in bone mineral density greater than the least amount of change that can be considered clinically significant, may occur in 10% or more of patients.⁴⁵ No treatment reduces fracture risk to zero. However, the presence of decreasing bone mineral density or the occurrence of multiple fractures should prompt evaluation and consideration of alternative therapy. Some clinicians measure bone-turnover markers 3 to 6 months after initiation of antiresorptive therapy to assess adher-

ence and response. Although declines in bone-turnover markers are associated with a reduction in fracture risk in large trials, this approach is not routinely recommended.

AREAS OF UNCERTAINTY

The appropriate duration of bisphosphonate therapy is unclear. In extended trials of alendronate (10 years) and zoledronate (6 years),^{46,47} participants who were assigned to discontinue therapy after 5 and 3 years, respectively, had lower bone mineral density at the study conclusion (although bone mineral density levels were higher than at pretreatment) and a higher incidence of vertebral (but not nonvertebral) fractures than participants who were assigned to continue treatment.^{46,47} Concerns regarding long-term bisphosphonate therapy center on atypical femur fractures.¹⁹ Among 196,129 women, the incidence of atypical femur fractures decreased from 4.50 per 10,000 person-years among current users of bisphosphonate to 1.81 per 10,000 person-years at 3 to 15 months after discontinuation and 0.5 per 10,000 person-years at more than 15 months after discontinuation.²⁰ Therefore, most guidelines recommend bisphosphonate “drug holidays” (temporary treatment breaks) to lower the risk of atypical femur fractures in women not at high risk for fracture after 5 years of treatment with oral bisphosphonate or 3 years of treatment with intravenous bisphosphonate.²² Treatment up to 10 years (oral administration) or 6 years (intravenous administration) is suggested in women at high risk (Table 3), with periodic reevaluation of the risks and benefits of continued treatment.²² Individualized decisions to resume bisphosphonates after a holiday should include the consideration of incident fractures, decreasing bone mineral density, increased bone-turnover markers to pretreatment values, and returns to intervention thresholds.¹¹ Likewise, the appropriate duration of denosumab is unclear. The Endocrine Society suggests reassessing fracture risk after 5 to 10 years of denosumab therapy and continuing or switching therapy in patients who remain at high risk. Because the risk of multiple vertebral fractures after discontinuation of therapy may rise as the duration of denosumab therapy increases, recommendations may evolve.⁴⁸

Limited data are available to guide the use of sequential pharmacologic treatment. Although antiresorptives are considered to be first-line therapy (Table 3), they blunt or delay bone mineral density gains in response to anabolic agents.^{49,50} In patients receiving treatment with bisphosphonates, switching to romosozumab led to greater increases in bone mineral density than teriparatide, although data regarding fractures are lacking.^{43,51-53} In contrast, switching patients from denosumab to teriparatide should be avoided owing to bone loss.⁵¹ Some experts recommend treat-to-target approaches, in which therapy is selected and modified according to the likelihood that it can decrease the patient's fracture risk to an acceptable level (e.g., T score greater than -2.0).⁵⁴ Appropriate thresholds are unclear and more data are needed to validate this approach.

GUIDELINES

Guidelines for diagnosis and management of postmenopausal osteoporosis vary with respect to the threshold for starting therapy and the choice and duration of treatment (Table 3). Our recommendations are generally consistent with the guidelines of the Endocrine Society and the Bone Health and Osteoporosis Foundation (Table 3).^{8,23,24}

CONCLUSIONS AND RECOMMENDATIONS

The presentation of the patient described in the vignette is typical of postmenopausal osteoporosis in that the initial humerus fracture was not recognized as indicating osteoporosis, which was later diagnosed by the T score of -2.6 and prevalent vertebral fractures. History and laboratory testing should identify modifiable risk factors, medications, and underlying conditions affecting fracture risk and therapy decisions. The patient's multiple fragility fractures indicate a very high risk of additional fractures. Therefore, we favor therapy with anabolic agents first with either a PTH receptor agonist or romosozumab followed by treatment with a bisphosphonate or denosumab. If anabolic therapy was declined, we would favor denosumab over bisphosphonates, given her severe osteoporosis and the greater effects of denosumab on bone mineral density. Despite the debated utility of repeat DXA, we would reevaluate clinically and reassess bone mineral density with DXA 1 or 2 years after initiating therapy.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

REFERENCES

1. Looker AC, Sarafrazi Isfahani N, Fan B, Shepherd JA. Trends in osteoporosis and low bone mass in older US adults, 2005-2006 through 2013-2014. *Osteoporos Int* 2017;28:1979-88.
2. Sarafrazi N, Wambogo EA, Shepherd JA. Osteoporosis or low bone mass in older adults: United States, 2017-2018. NCHS data brief. No 405. Hyattsville, MD: National Center for Health Statistics, 2021 (<https://www.cdc.gov/nchs/data/databriefs/db405-H.pdf>).
3. Dyer SM, Crotty M, Fairhall N, et al. A critical review of the long-term disability outcomes following hip fracture. *BMC Geriatr* 2016;16:158.
4. LeBlanc ES, Hillier TA, Pedula KL, et al. Hip fracture and increased short-term but not long-term mortality in healthy older women. *Arch Intern Med* 2011;171:1831-7.
5. Penrod JD, Litke A, Hawkes WG, et al. The association of race, gender, and comorbidity with mortality and function after hip fracture. *J Gerontol A Biol Sci Med Sci* 2008;63:867-72.
6. Lewiecki EM, Ortendahl JD, Vanderpuye-Orgle J, et al. Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States. *JBM Plus* 2019;3(9):e10192.
7. Stone KL, Seeley DG, Lui L-Y, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. *J Bone Miner Res* 2003;18:1947-54.
8. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int* 2022;33:2049-102.
9. Kanis JA, Cooper C, Rizzoli R, Reginster J-Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* 2019;30:3-44.
10. Qaseem A, Hicks LA, Etzeandia-Ikobaltzeta I, et al. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. *Ann Intern Med* 2023;176:224-38.
11. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis — 2020 update: executive summary. *Endocr Pract* 2020;26:564-70.
12. van den Bergh JP, van Geel TA, Geusens PP. Osteoporosis, frailty and fracture: implications for case finding and therapy. *Nat Rev Rheumatol* 2012;8:163-72.
13. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. *Lancet* 1999;353:878-82.
14. Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. *Osteoporos Int* 2014;25:1439-43.
15. Hans D, Goertzen AL, Krieg M-A, Leslie WD. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. *J Bone Miner Res* 2011;26:2762-9.
16. Samelson EJ, Broe KE, Xu H, et al. Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. *Lancet Diabetes Endocrinol* 2019;7:34-43.
17. Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for



the prevention of fractures in postmenopausal women: a network meta-analysis. *J Clin Endocrinol Metab* 2019;104:1623-30.

18. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. *N Engl J Med* 2016;375:1532-43.

19. Siu A, Allore H, Brown D, Charles ST, Lohman M. National Institutes of Health pathways to prevention workshop: research gaps for long-term drug therapies for osteoporotic fracture prevention. *Ann Intern Med* 2019;171:51-7.

20. Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. *N Engl J Med* 2020;383:743-53.

21. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. *N Engl J Med* 2017;377:1417-27.

22. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2016;31:16-35.

23. Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. *J Clin Endocrinol Metab* 2020;105:587-94.

24. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. *J Clin Endocrinol Metab* 2019;104:1595-622.

25. McCloskey EV, Johansson H, Oden A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. *J Bone Miner Res* 2012;27:1480-6.

26. Shepstone L, Lenaghan E, Cooper C, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. *Lancet* 2018;391:741-7.

27. Guirguis-Blake JM, Michael YL, Perdue LA, Coppola EL, Beil TL. Interventions to prevent falls in older adults: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2018;319:1705-16.

28. Hoffmann I, Kohl M, von Stengel S, et al. Exercise and the prevention of major osteoporotic fractures in adults: a systematic review and meta-analysis with special emphasis on intensity progression and study duration. *Osteoporos Int* 2023;34:15-28.

29. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. *BMJ* 2010;341:c3691.

30. Bone HG, Wagman RB, Brandi ML, et al. 10 Years of denosumab treatment in

postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. *Lancet Diabetes Endocrinol* 2017;5:513-23.

31. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. *J Bone Miner Res* 2009;24:153-61.

32. Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. *J Bone Miner Res* 2018;33:190-8.

33. Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. *Osteoporos Int* 2012;23:317-26.

34. Makras P, Appelman-Dijkstra NM, Papapoulos SE, et al. The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. *J Clin Endocrinol Metab* 2021;106(10):e4155-e4162.

35. Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. *J Clin Endocrinol Metab* 2021;106:264-81.

36. Lyu H, Yoshida K, Zhao SS, et al. Delayed denosumab injections and fracture risk among patients with osteoporosis: a population-based cohort study. *Ann Intern Med* 2020;173:516-20.

37. Black DM, Bauer DC, Vittinghoff E, et al. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. *Lancet Diabetes Endocrinol* 2020;8:672-82.

38. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. *N Engl J Med* 2005;353:555-65.

39. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. *JAMA* 2016;316:722-33.

40. Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. *Lancet* 2018;391:230-40.

41. Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal

osteoporosis. *J Clin Endocrinol Metab* 2010;95:1838-45.

42. Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB. Teriparatide did not increase adult osteosarcoma incidence in a 15-year US post-marketing surveillance study. *J Bone Miner Res* 2021;36:244-51.

43. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. *N Engl J Med* 2014;370:412-20.

44. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. *Lancet* 2013;382:50-6.

45. Lewiecki EM. Nonresponders to osteoporosis therapy. *J Clin Densitom* 2003;6:307-14.

46. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. *JAMA* 2006;296:2927-38.

47. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). *J Bone Miner Res* 2012;27:243-54.

48. Cosman F, Huang S, McDermott M, Cummings SR. Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. *J Bone Miner Res* 2022;37:2112-20.

49. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. *J Clin Endocrinol Metab* 2008;93:3785-93.

50. Cosman F, Kendler DL, Langdahl BL, et al. Romosozumab and antiresorptive treatment: the importance of treatment sequence. *Osteoporos Int* 2022;33:1243-56.

51. Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. *Lancet* 2015;386:1147-55.

52. Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. *J Bone Miner Res* 2019;34:419-28.

53. Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. *Lancet* 2017;390:1585-94.

54. Lewiecki EM. Operationalizing treatment-target for osteoporosis. *Endocrinol Metab (Seoul)* 2021;36:270-8.

Copyright © 2023 Massachusetts Medical Society.

Classified Advertising Section

Sequence of Classifications

Addiction Medicine	Neonatal-Perinatal Medicine	Preventive Medicine	Urology
Allergy & Clinical Immunology	Nephrology	Primary Care	Chiefs/Directors/ Department Heads
Ambulatory Medicine	Neurology	Psychiatry	Faculty/Research
Anesthesiology	Nuclear Medicine	Public Health	Graduate Training/Fellowships/ Residency Programs
Cardiology	Obstetrics & Gynecology	Pulmonary Disease	Courses, Symposia, Seminars
Critical Care	Occupational Medicine	Radiation Oncology	For Sale/For Rent/Wanted Locum Tenens
Dermatology	Ophthalmology	Radiology	Miscellaneous
Emergency Medicine	Osteopathic Medicine	Rheumatology	Multiple Specialties/ Group Practice
Endocrinology	Otolaryngology	Surgery, General	Part-Time Positions/Other Physician Assistant
Family Medicine	Pathology	Surgery, Cardiovascular/ Thoracic	Physician Services
Gastroenterology	Pediatrics, General	Surgery, Neurological	Positions Sought
General Practice	Pediatric Gastroenterology	Surgery, Orthopedic	Practices for Sale
Geriatrics	Pediatric Intensivist/ Critical Care	Surgery, Pediatric	
Hematology-Oncology	Pediatric Neurology	Surgery, Plastic	
Hospitalist	Pediatric Otolaryngology	Surgery, Transplant	
Infectious Disease	Pediatric Pulmonology	Surgery, Vascular	
Internal Medicine	Physical Medicine & Rehabilitation	Urgent Care	
Internal Medicine/Pediatrics			
Medical Genetics			

Classified Advertising Rates

We charge \$10.85 per word per insertion. A 2- to 4-time frequency discount rate of \$8.10 per word per insertion is available. A 5-time frequency discount rate of \$7.75 per word per insertion is also available. In order to earn the 2- to 4-time or 5-time discounted word rate, the request for an ad to run in multiple issues must be made upon initial placement. The issues do not need to be consecutive. **Web fee:** Classified line advertisers may choose to have their ads placed on NEJM CareerCenter for a fee of \$135.00 per issue per advertisement. The web fee must be purchased for all dates of the print schedule. The choice to place your ad online must be made at the same time the print ad is scheduled. **Note:** The minimum charge for all types of line advertising is equivalent to 30 words per ad. Purchase orders will be accepted subject to credit approval. For orders requiring prepayment, we accept payment via Visa, MasterCard, and American Express for your convenience, or a check. All classified line ads are subject to the consistency guidelines of NEJM.

How to Advertise

All orders, cancellations, and changes must be received in writing. E-mail your advertisement to us at ads@nejmcareercenter.org, or fax it to 1-781-895-1045 or 1-781-893-5003. We will contact you to confirm your order. Our closing date is typically the Friday 20 days prior to publication date; however, please consult the rate card online at nejmcareercenter.org or contact the Classified Advertising Department at 1-800-635-6991. Be sure to tell us the classifica-

tion heading you would like your ad to appear under (see listings above). If no classification is offered, we will determine the most appropriate classification. Cancellations must be made 20 days prior to publication date. Send all advertisements to the address listed below.

Contact Information

Classified Advertising
The New England Journal of Medicine
860 Winter Street, Waltham, MA 02451-1412
E-mail: ads@nejmcareercenter.org
Fax: 1-781-895-1045
Fax: 1-781-893-5003
Phone: 1-800-635-6991
Phone: 1-781-893-3800
Website: nejmcareercenter.org

How to Calculate the Cost of Your Ad

We define a word as one or more letters bound by spaces. Following are some typical examples:

Bradley S. Smith III, MD..... = 5 words
Send CV = 2 words
December 10, 2007 = 3 words
617-555-1234 = 1 word
Obstetrician/Gynecologist ... = 1 word
A = 1 word
Dalton, MD 01622 = 3 words

As a further example, here is a typical ad and how the pricing for each insertion is calculated:

MEDICAL DIRECTOR — A dynamic, growth-oriented home health care company is looking for a full-time Medical Director in greater New York. Ideal candidate should be board certified in internal

medicine with subspecialties in oncology or gastroenterology. Willing to visit patients at home. Good verbal and written skills required. Attractive salary and benefits. Send CV to: E-mail address.

This advertisement is 56 words. At \$10.85 per word, it equals \$607.60. This ad would be placed under the Chiefs/Directors/ Department Heads classification.

Classified Ads Online

Advertisers may choose to have their classified line and display advertisements placed on NEJM CareerCenter for a fee. The web fee for line ads is \$135.00 per issue per advertisement and \$230.00 per issue per advertisement for display ads. The ads will run online two weeks prior to their appearance in print and one week after. For online-only recruitment advertising, please visit nejmcareercenter.org for more information, or call 1-800-635-6991.

Policy on Recruitment Ads

All advertisements for employment must be non-discriminatory and comply with all applicable laws and regulations. Ads that discriminate against applicants based on sex, age, race, religion, marital status or physical handicap will not be accepted. Although the *New England Journal of Medicine* believes the classified advertisements published within these pages to be from reputable sources, NEJM does not investigate the offers made and assumes no responsibility concerning them. NEJM strives for complete accuracy when entering classified advertisements; however, NEJM cannot accept responsibility for typographical errors should they occur.



Embark on the path to make health care better for everyone.

Are you ready to put your medical training into practice? Get a head start on your career at Optum, the largest network of medical groups and care providers in the country.

We're proud to introduce our **Physician Pathways Program**, designed exclusively for career-minded final-year residents and fellows who want to commit to early employment post-training. You'll receive financial support for participating in our mentorship program, which will enhance your training and equip you with extra skills for a successful transition into private practice.

As a participant in the Physician Pathways Program, you will:

- Receive a salary that allows you to focus on your training and career development, all while enhancing your final-year training experience, because you've removed the stress of searching for a job.
- Meet your leaders and peers months prior to starting your physician career. This will give you a head start on building important relationships.
- Gain exposure to the Quadruple Aim framework as you learn how to thrive in a value-based care model. Optum is driving population health initiatives and developing best practices that are being adopted nationally.

Prepare for a better future with Optum.

Optum is a truly remarkable place to practice medicine. Our team-based model of care places physicians and patients at the center of care, giving you the freedom and flexibility to be better.

Better at caring for your patients. Better at caring for yourself. Better at making health care better for everyone. Better at creating a career path without limits. Optum serves patients from coast to coast with 90,000 aligned physicians and advanced practice clinicians – all **Caring. Connecting. Growing together.**

Visit [Optum.co/Pathways](https://optum.co/pathways) to view current opportunities. Or scan the QR code below.



Classified Ad Deadlines

Issue	Closing Date
March 21/28	March 1
April 4	March 15
April 11	March 22
April 25	April 5

Hematology-Oncology

SOUTHEAST FLORIDA, OUTSTANDING OPPORTUNITY FOR NEW LOCATION — Seeking Hematologist/Oncologist, BE/BC. To join busy well-established growing private practice. The group consists of six physicians and nine Physician Extenders with five locations. Position offers competitive compensation, sign-on bonus, and excellent benefits. Beautiful coastal community, north of Palm Beach. Accepting H1/B, J1 applicants. Please e-mail CV to: hgowda@stuartoncology.com or call: 941-993-7578.

For the right opportunity, you need the leading source of information.

NEJMCareerCenter.org

LOS ANGELES HEMATOLOGY/ONCOLOGY — Private Oncology Practice with multiple locations in Los Angeles area looking for BC/BE Oncologists to join our thriving and rapidly growing practice. Excellent compensations and benefits, including Malpractice, Health/Dental, bonuses. Nice work schedule (99% office or Telemed) and easy weekend calls. Your application will be kept strictly confidential. CV To: Socalonc@gmail.com; or Text/Call: 323-691-0990.

If recruiting top physicians is important to you, advertise in the source that's important to them.

NEJM CareerCenter
(800) 635-6991
ads@nejmcareercenter.org

Nephrology

ADULT NEPHROLOGIST NEEDED — Third Nephrologist to join private practice in Orlando suburb area of Florida. Excellent salary and benefit package. Please send e-mail/CV to: Yogeeta0778@gmail.com

Advertise in the next Career Guide.

For more information, contact:
(800) 635-6991
ads@nejmcareercenter.org

Jobs for you, right to your inbox.

Sign up for FREE physician job alerts today!

It's quick and easy to set up and can give you a valuable edge in finding your next job. Simply set your specialty and location and we'll automatically send you new jobs that match your criteria.

Get started now at: nejmcareercenter.org/newalert



E M E R S O N H E A L T H O P P O R T U N I T I E S



Location, Location, Location

Emerson Health has several opportunities for board-certified or board-eligible physicians to join several practices located throughout our service area. Emerson has employed as well as private practice opportunities.

At Emerson, you will find desirable practice locations, strong relationships with academic medical centers, superb quality of life, competitive financial packages, and more.

Emerson Health Opportunities:

- Cardiology**
 - Non-invasive
- Urology**
- Hospitalist**
 - Daytime, Nocturnist and Moonlighters
- Orthopedics**
- Primary Care**
 - Employed and Private Practice
- Psychiatrist**
 - Full-time and Moonlighting

For more information please contact:

Diane Forte Willis
Director of Physician Recruitment and Relations
dfortewillis@emersonhosp.org
Phone: 978-287-3002
Fax: 978-287-3600

About Concord, MA and Emerson Health

Emerson Health is a regional health care system providing advanced medical services to more than 300,000 people in 25 towns. We make high-quality healthcare more accessible to those who live and work in our community at Emerson Hospital in Concord, health centers in Bedford, Groton, Sudbury, Westford and Concord and Urgent Care settings in Hudson, Littleton and Maynard.

Emerson has strategic alliances with several academic centers in Boston including Mass General Brigham and Massachusetts Eye and Ear Infirmary.

Concord is known for its rich history, revolutionary war sites and many famous authors. The surrounding communities are among the best places to live in Massachusetts with several top-ranked school systems in the state and is located just 20 miles Northwest of Boston.



emersonhealth.org



Together,
for the
healthiest lives



We celebrate the different perspectives, backgrounds, and experiences our physicians bring to their work every day at Intermountain Health. Throughout our integrated health system, we proudly share best practices, knowledge, and techniques to better serve our patients, communities, and each other.

Here, you'll work alongside collaborative and curious minds who will support you, encourage you, inspire you, advocate for you, and challenge you to be your very best.

providersourcing@imail.org | PhysicianJobsIntermountain.org

NEJM CareerCenter

SEARCH AND APPLY FOR JOBS FROM YOUR IPHONE.

- Search or browse quality physician jobs by specialty and/or location
- Receive notification of new jobs that match your search criteria
- Save jobs with the touch of a button
- Email or tweet jobs to your network
- Apply for jobs directly from your phone!



Download or update the FREE app and start your search today!

NEJMCareerCenter.org

NEJM Knowledge+

Strengthen your knowledge.
Improve your patient care.

NEJM Knowledge+ is the most efficient, engaging, and effective way for you to learn, improve the quality of your practice, and prepare for board exams. Choose the product for you.

- + NEJM Knowledge+ Internal Medicine Board Review
- + NEJM Knowledge+ Family Medicine Board Review

With features that save you time and ensure your success

- Personalized learning, tailored to you
- Extensive question banks that reflect ABIM, ABFM, and NCCPA exam blueprints
- Ability to earn CME, AAFP Prescribed credits, and MOC points
- Two timed practice exams
- Convenient mobile access via iPad, iPhone, Android devices



Learn more at <http://knowledgeplus.nejm.org/special12b>



TriHealth

TriHealth in Cincinnati, Ohio, is welcoming engaging, top-talent physicians in:

Cardiology – AHF and Non-Invasive
Dermatology • Infectious Diseases
Otolaryngology • PM&R
Pulmonology/Critical Care

Enjoy a strong referral stream from the largest Primary Care network in the region, healthy sign-on bonus and attractive relocation.

Be seen. Be heard. Be here...
healing begins with you.

Contact:
Melissa_Jansing@TriHealth.com
859 653 1392 / TriHealth.com

What will
you learn
today?



As a medical professional in a constantly evolving health care environment, you understand the importance of continuous learning. From breakthrough medical research and educational offerings to analysis and clinical insights, NEJM Group delivers trustworthy information that inspires, challenges, and supports you in your work to improve patient care.


Learn more at NEJMGROUP.ORG



NEJM Catalyst | Innovations in Care Delivery

A journal for transforming health care delivery

NEJM Catalyst Innovations in Care Delivery, a peer-reviewed digital journal for health care leaders, explores the best ideas and strategies with the most potential for change. Learn more today.



SUBSCRIBE TODAY AT CATALYST.NEJM.ORG



At the end of your training,
where do you want to be?



JOIN INDUSTRY-LEADING BANNER HEALTH IN ARIZONA!
We're expanding our Cardiology footprint in Phoenix & Tucson.



Banner Medical Group (BMG) & Banner University Medical Group (BUMG) are actively recruiting **Cardiology Fellows (Interventional | Non-Invasive | EP)** to join our growing teams in Phoenix & Tucson!

We offer a generous salary, sign-on and recruitment incentives, along with an industry leading benefits package that provides security for you and your family!

Banner Health is one of the largest non-profit healthcare systems in the nation with 30 hospitals (15 in Arizona), including University of Arizona academic campuses in Phoenix and Tucson, six long term care centers and hundreds of primary care and multi-specialist clinics in six Western states. Banner Health promotes collaborative team-oriented workplaces and clinical settings that focus on providing excellent patient care. We are physician-led, and value the voice of our providers. We take pride in being integrated and innovative, developing ways to make Health Care Made Easier, Life Made Better.

- Comprehensive medical, dental, vision & pharmacy plans | eligible for benefits within 30 days
- ATO & CME days, with reimbursement
- Paid malpractice, licensure & DEA registration fees
- 401K 4% match after one year of service
- Financial savings resources & mortgage assistance
- Leadership & career advancement with optimal work/life balance



Banner Health.

SUBMIT YOUR CV FOR IMMEDIATE CONSIDERATION
Join our Talent Community: PracticewithUs.Bannerhealth.com

Be seen as a person, not just a CV.

With everything going on, it's easy to become a faceless cog in the machine of healthcare. If you're looking to reconnect with your passion for medicine, we can help you find the perfect job that's tailored to who you are, not just what you are.

From locum tenens to permanent placements, let's find the change that's right for you.

www.comphealth.com/n-mostpersonalized



CompHealth

WE GET WHAT MATTERS
TO YOU MOST.

DHA CIVILIAN PHYSICIANS GET THE WORK-LIFE BALANCE THEY NEED & THE BENEFITS THEY DESERVE.

- Competitive Salary
- Job Security
- Generous Paid Time Off
- Supportive Work Environment
- Flexible Schedules
- 350+ Worldwide Locations



DHA employees are NOT subject to military requirements such as "boot camp," enlistments, or deployments. Department of Defense is an equal opportunity employer.

FIND JOBS | POST YOUR CV | LEARN MORE
CIVILIANMEDICALJOBS.COM



DHA
Defense Health Agency

REACH NEW HEIGHTS
IN YOUR LIFE AND IN
YOUR CAREER.



Come to Colorado and help make extraordinary things possible. Join us today.

JENNIFER KOLLMAN, MD
Anesthesiology

To apply, scan the QR code or visit joinuhealth.org.



Come join our team of Hospitalists!

(day and night, teaching and non-teaching opportunities)

Harvard Medical Faculty Physicians at
Beth Israel Deaconess Medical Center - Boston, MA

The Hospital Medicine team at Beth Israel Deaconess is seeking **Physicians** and **Advanced Practice Professionals (APPs)** for day and night, teaching and non-teaching opportunities at its Harvard-affiliated teaching hospital in Boston and at community hospitals in Milton, Needham and Plymouth. We are also seeking an **Associate Site Director** at our hospital in Plymouth. A medical school faculty appointment may also be possible. To learn more or apply, please contact Dr. Li and Dr. Phillips below.

Joseph Li, MD - Chief of Hospital Medicine
JLi2@bidmc.harvard.edu
and

Rusty Phillips, MD - Director of Recruitment
wphillip@bidmc.harvard.edu

Scan this QR Code to learn more about our group and our professional development opportunities.



We are an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status, gender identity, sexual orientation, pregnancy and pregnancy-related conditions or any other characteristic protected by law.

Harvard Medical Faculty Physicians
at Beth Israel Deaconess Medical Center

HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

and at our affiliates
Beth Israel Lahey Health

Vital Roles in a Vibrant Community Physician Opportunities

BERKSHIRE HEALTH SYSTEMS IS SEEKING COMPASSIONATE, COMMUNITY-FOCUSED PHYSICIANS IN THE FOLLOWING DISCIPLINES:

- ANESTHESIOLOGY • CARDIOLOGY
- DERMATOLOGY • ENDOCRINOLOGY
- ENT • FAMILY MEDICINE • GASTROENTEROLOGY
- HEMATOLOGY/ONCOLOGY • NEUROLOGY
- NEPHROLOGY • OB-GYN • PSYCHIATRY
- PRIMARY CARE • RHEUMATOLOGY • UROLOGY

Berkshire Health Systems (BHS) is the leading provider of comprehensive healthcare services for residents and visitors to Berkshire County, in western Massachusetts. From inpatient surgery and cancer care to provider visits and imaging, BHS offers a continuum of programs and services that help patients to connect to the care they need, no matter where they are located in the rural Berkshire community. As the largest employer in Berkshire County, BHS supports more than 4,000 jobs in the region, and, as a 501(c)(3) nonprofit organization, BHS is committed to partnering with local municipalities and community organizations to help the county thrive. Working at BHS offers a unique opportunity to both practice and teach in a state-of-the-art clinical environment at Berkshire Medical Center, the system's 298-bed community teaching hospital in Pittsfield, which is a major teaching affiliate of the University of Massachusetts Chan Medical School and the University of New England College of Osteopathic Medicine in Maine.


At BHS, we also understand the importance of balancing work with quality of life. The Berkshires, a 4-season resort community, offers world renowned music, art, theater, and museums, as well as year round recreational activities from skiing to kayaking. Excellent public and private schools make this an ideal family location. We are also only a 2½ hours drive from both Boston and New York City.

Contact us to learn more about these exciting opportunities to practice in a beautiful and culturally rich region, as part of a sophisticated, award-winning, patient-centered healthcare team.

Interested candidates are invited to contact:

Michelle Maston or Cody Emond
Provider Recruitment, Berkshire Health Systems
(413) 447-2784 | mmaston@bhs1.org
cemond@bhs1.org


Apply online at: berkshirehealthsystems.org



Our locums experts help you get where you want to go.

We're committed to providing you with the best locums jobs. Our team of experts will simplify the staffing process and ensure you're prepared for success.

weatherbyhealthcare.com



Optum

Together, we can all be better.

At Optum, we are making health care human again by giving clinicians the freedom and flexibility to be better.

Better at caring for your patients. Better at caring for yourself. Better at creating a career path without limits. Better at making health care exceptional for everyone.

As the largest network of medical groups in the country, Optum serves patients from coast to coast with 90,000 aligned physicians and advanced practice clinicians – all **Caring. Connecting. Growing together.**



Are you ready for a change?

Come practice with Optum and build a better future.



Search Optum physician careers.